TC方案联合放疗对于高危子宫内膜癌术后疗效及安全性分析.docVIP

TC方案联合放疗对于高危子宫内膜癌术后疗效及安全性分析 　　[摘要] 目的 评价TC方案联合放疗作为高危子宫内膜癌术后辅助治疗的临床疗效并分析其安全性。方法 整群选取2014年7月―2016年7月期间首次于该院就诊并行规范手术的高危子宫内膜癌患者96例，随机均分两组，每组48例。治疗组TC方案联合放疗，对照组给予放疗，比较2组患者的复发率、转移率、5年生存率等。结果 治疗组局部复发率与远处转移率均较对照组低（4.2% vs 18.8%，χ2=5.031，P=0.025），而5年总生存率则高于对照组（6.3% vs 20.8%，χ2=4.360，P =0.037）。治疗组中虽然骨髓抑制反应较对照组发生差异有统计学意义（89.6% vs 70.8%，χ2=5.315，P =0.021），经药物治疗可逐渐恢复。结论 TC方案联合放疗对于术后高危子宫内膜癌患者是较佳的辅助治疗方案，安全可靠。 　　[关键词] 放疗；化疗；子宫内膜癌 　　[中图分类号] R737.33 [文献标识码] A [文章编号] 1674-0742（2016）10（c）-0121-03 　　[Abstract] Objective To evaluate the efficacy and safety of TC regimen combined with radiotherapy as adjuvant therapy for high-risk endometrial cancer patients. Methods Group selection the first time received treatment in our hospital， 96 patients with high-risk endometrial cancer were randomly divided into two groups. 48 cases in the treatment group were treated with TC regimen combined with radiotherapy. 48 cases in the control group were treated by radiotherapy alone. The recurrence rate， metastasis rate， 5 year survival rate and drug toxicity of the 2 groups were compared. Results The local recurrence rate and distant metastasis rate in the treatment group were significantly lower than that in the control group（4.2% vs 18.8%，χ2=5.031，P =0.025）. While the 5 year overall survival rate was significantly higher than that in the control group（6.3% vs 20.8%，χ2=4.360，P =0.037）. Although the bone marrow inhibition reaction in the treatment group was significantly higher than that of the control group （89.6% vs 70.8%，χ2=5.315，P =0.021）， but the treatment group could be recovered gradually through drug therapy. Conclusion TC regimen combined with radiotherapy for patients with high-risk endometrial cancer is a better adjuvant therapy， safe and reliable. 　　[Key words] Radiotherapy； Chemotherapy； Endometrial carcinoma 　　子宫内膜癌在妇科恶性肿瘤比例约占40%[1]。放疗可明显抑制肿瘤的局部复发，而延长患者的生存期却不乐观，但化疗对改善患者预后有一定帮助，目前，对于子宫内膜癌术后辅助化疗常用紫杉醇联合铂类，而关于TC联合放疗的研究较少。该院整群选取2014年7月―2016年7月期间首次于该院就诊并行规范手术的高危子宫内膜癌患者96例，进行了相关研究，现报道如下。